Bal Pharma Share Price
Start SIP in Bal Pharma
Start SIPBal Pharma Performance
Day Range
- Low 133
- High 139
52 Week Range
- Low 81
- High 158
- Open Price134
- Previous Close137
- Volume19391
Bal Pharma Investment Rating
-
Master Rating:
-
Bal Pharma has an operating revenue of Rs. 343.19 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 3% needs improvement, ROE of 10% is good. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 19% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 78 which is a FAIR score but needs to improve its earnings, a RS Rating of 56 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 58 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 73 | 95 | 81 | 92 | 70 | 82 |
| Operating Expenses Qtr Cr | 66 | 84 | 74 | 85 | 63 | 74 |
| Operating Profit Qtr Cr | 7 | 10 | 8 | 8 | 7 | 8 |
| Depreciation Qtr Cr | 2 | 2 | 3 | 2 | 2 | 2 |
| Interest Qtr Cr | 4 | 4 | 4 | 4 | 4 | 4 |
| Tax Qtr Cr | 0 | 0 | 0 | 1 | 0 | 1 |
| Net Profit Qtr Cr | 2 | 6 | 1 | 2 | 1 | 2 |
Bal Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 11
- Bearish Moving Average
- ___
- 5
- 20 Day
- ₹134.17
- 50 Day
- ₹126.94
- 100 Day
- ₹120.23
- 200 Day
- ₹113.08
- 20 Day
- ₹134.18
- 50 Day
- ₹125.07
- 100 Day
- ₹116.49
- 200 Day
- ₹112.47
Bal Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 138.08 |
| Second Resistance | 141.30 |
| Third Resistance | 143.70 |
| RSI | 52.67 |
| MFI | 86.38 |
| MACD Single Line | 5.02 |
| MACD | 3.90 |
| Support | |
|---|---|
| First Support | 132.46 |
| Second Support | 130.06 |
| Third Supoort | 126.84 |
Bal Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 21,686 | 2,168,600 | 100 |
| Week | 34,488 | 3,448,820 | 100 |
| 1 Month | 309,164 | 13,207,470 | 42.72 |
| 6 Month | 94,069 | 4,628,175 | 49.2 |
Bal Pharma Result Highlights
Bal Pharma Synopsis
NSE-Medical-Diversified
Bal Pharma Ltd belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 303.10 Cr. and Equity Capital is Rs. 15.69 Cr. for the Year ended 31/03/2023. Bal Pharma Ltd. is a Public Limited Listed company incorporated on 19/05/1987 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L85110KA1987PLC008368 and registration number is 008368.| Market Cap | 218 |
| Sales | 342 |
| Shares in Float | 0.78 |
| No of funds | 1 |
| Yield | 0.88 |
| Book Value | 2.05 |
| U/D Vol ratio | 3.8 |
| LTDebt / Equity | 34 |
| Alpha | 0.03 |
| Beta | 1.29 |
Bal Pharma Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 51.23% | 51.23% | 51.23% | 51.61% |
| Foreign Portfolio Investors | 0.13% | 0.13% | 0.13% | 0.14% |
| Individual Investors | 32.35% | 32.15% | 32.64% | 32.19% |
| Others | 16.29% | 16.49% | 16% | 16.06% |
Bal Pharma Management
| Name | Designation |
|---|---|
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Dr. C V Srinivas | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Independent Director |
| Mr. Kotian Chittananda Damodar | Executive Director |
Bal Pharma Forecast
Price Estimates
Bal Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-12 | Quarterly Results, ESOP & A.G.M. | |
| 2024-05-28 | Audited Results & Final Dividend | |
| 2024-02-12 | Quarterly Results | |
| 2023-11-08 | Quarterly Results & ESOP | |
| 2023-08-11 | Quarterly Results & A.G.M. |
Bal Pharma FAQs
What is Share Price of Bal Pharma ?
Bal Pharma share price is ₹134 As on 11 September, 2024 | 21:08
What is the Market Cap of Bal Pharma ?
The Market Cap of Bal Pharma is ₹214.7 Cr As on 11 September, 2024 | 21:08
What is the P/E ratio of Bal Pharma ?
The P/E ratio of Bal Pharma is 28.4 As on 11 September, 2024 | 21:08
What is the PB ratio of Bal Pharma ?
The PB ratio of Bal Pharma is 3.1 As on 11 September, 2024 | 21:08